Abiopharma

🔍 Inglis Tiffany Eul Davis (Executive)

Company: SERA PROGNOSTICS, INC. (SERA)

Report Date: 2026-03-12

Detailed Transactions and Holdings:

• Acquired 17,437 shares of Class A Common Stock (Direct)
  Date: 2026-03-12 | Code: A | equity_swap_involved: false | shares_owned_after: 92,437.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 27,034 shares of Stock Option (right to buy) at $1.99 per share (Derivative)
  Date: 2026-03-12 | Code: A | Expires: 2036-03-12 | equity_swap_involved: false | shares_owned_after: 27,034.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over four years as follows: 1/16 of the original grant amount vests in quarterly installments for four years following the vesting commencement date, which is March 10, 2026, subject to the Reporting Person continuing to provide services to the issuer.
• F2: These stock options vest over four years as follows: 1/48 of the original grant amount vests in monthly installments for four years following the vesting commencement date, which is March 10, 2026, subject to the Reporting Person continuing to provide services to the issuer.